(Q83199953)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22231235%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

SSc in 2011: From mechanisms to medicines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22231235%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Luc Mouthon

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22231235%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

10 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22231235%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22231235%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22231235%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22231235%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

72-74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22231235%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrrheum.2011.203

20 January 2020

exact match

0 references

cites work

Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

Imatinib as a novel therapeutic approach for fibrotic disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

Platelet-derived serotonin links vascular disease and tissue fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203

Platelet contributions to the pathogenesis of systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.203